ID: ALA2326076

Max Phase: Preclinical

Molecular Formula: C35H42O5

Molecular Weight: 542.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOC(=O)CC(=O)c1ccc(C#CCCCC[C@@H]2Cc3cc(O)ccc3[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]23)cc1

Standard InChI:  InChI=1S/C35H42O5/c1-3-40-33(39)22-31(37)24-12-10-23(11-13-24)8-6-4-5-7-9-25-20-26-21-27(36)14-15-28(26)29-18-19-35(2)30(34(25)29)16-17-32(35)38/h10-15,21,25,29-30,32,34,36,38H,3-5,7,9,16-20,22H2,1-2H3/t25-,29-,30+,32+,34-,35+/m1/s1

Standard InChI Key:  DWTNKXOQSZYRNO-JREWWFGGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 542.72

Molecular Weight (Monoisotopic): 542.3032

AlogP: 6.58

#Rotatable Bonds: 8

Polar Surface Area: 83.83

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.18

CX Basic pKa:

CX LogP: 7.37

CX LogD: 7.37

Aromatic Rings: 2

Heavy Atoms: 40

QED Weighted: 0.13

Np Likeness Score: 1.43

References

1. Jiang XR, Wang P, Smith CL, Zhu BT..  (2013)  Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.,  56  (7): [PMID:23448346] [10.1021/jm3013773]

Source

Source(1):

• Scientific Literature